Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07566390 · ClinicalTrials.gov registry record · Phase 1

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

A Phase 1 study, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target

NCT07566390: Recruiting Phase 1 study, sponsored by Novo Nordisk A/S.

NCT07566390 is a Phase 1 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07566390, a Phase 1 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.

Primary Outcome

Measured as number of events.

Interventions

  • DRUG Placebo
  • DRUG NNC0113-5840

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2026-05-01
Est. Completion 2026-11-26
Phase Phase 1
Novo Nordisk A/S

431 total trials

What NCT07566390 shows while recruiting

NCT07566390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07566390 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07566390 about?

NCT07566390 is a clinical study titled "A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity". The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which trea...

What is the current status of trial NCT07566390?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-05-01. Estimated completion is 2026-11-26.

What interventions are being tested in trial NCT07566390?

The interventions under investigation include: Placebo (DRUG), NNC0113-5840 (DRUG).

Who is sponsoring clinical trial NCT07566390?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07566390's enrollment target sits among peer trials

48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07566390, the US trial registry maintained by the National Library of Medicine. NCT07566390 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.